Earnings Call Summary | BWX Technologies(BWXT.US) Q1 2024 Earnings Conference
Earnings Call Summary | BWX Technologies(BWXT.US) Q1 2024 Earnings Conference
The following is a summary of the BWX Technologies, Inc. (BWXT) Q1 2024 Earnings Call Transcript:
以下是BWX Technologies, Inc.（BWXT）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
BWX Technologies reported a 6% organic revenue growth and 9% adjusted earnings per share growth in Q1 2024.
The company forecasts full-year mid-single-digit revenue and adjusted EBITDA growth, leading to adjusted earnings per share of $3.05 to $3.20.
BWX Technologies报告称，2024年第一季度有机收入增长6％，调整后每股收益增长9％。
该公司预测全年中期个位数收入和调整后的息税折旧摊销前利润增长，调整后的每股收益为3.05美元至3.20美元。
Business Progress:
业务进展：
BWXT is investing $60m to expand and upgrade its Cambridge plant and expects to see a 25% revenue growth for BWXT Medical this year due to strong demand.
Its existing commercial nuclear backlog exceeds $700m, and they have secured a two-year extension for their downblending contract.
The company's microreactor projects for land and sea, including Project Pele, are progressing well, and their drug master file for Lutetium and other APIs is underway.
BWXT is developing its capacity and workforce to sustain higher production rates, having hired 10% of its workforce over the past year.
BWXT正在投资6000万美元扩建和升级其剑桥工厂，由于需求强劲，预计今年BWXT Medical的收入将增长25％。
其现有的商用核电积压超过7亿美元，他们已确保将稀释合同延期两年。
该公司的陆地和海上微反应器项目，包括贝利项目，进展顺利，他们的Lutetium和其他原料药的药物主文件正在进行中。
BWXT正在发展其产能和员工队伍，以维持更高的生产率，在过去的一年中雇用了10％的员工。
More details: BWX Technologies IR
更多详情： BWX 科技 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。无法完全保证内容的准确性。欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。